By Colin Kellaher
Labcorp Holdings has signed a deal to buy certain assets of OPKO Health's BioReference Health unit for up to $225 million.
Labcorp on Tuesday said it will pay $192.5 million at closing for BioReference's laboratory testing businesses, which is focused on oncology and oncology-related clinical testing services across the U.S.
The Burlington, N.C., provider of laboratory services said the deal includes a performance-based earnout of up to $32.5 million, adding that the acquired assets generate $85 million to $100 million in annual revenue.
Miami-based biopharmaceutical and diagnostics company OPKO said BioReference's remaining operations will include its core clinical testing operations in the New York and New Jersey region and its 4Kscore franchise, which represented about $300 million in revenue for 2024.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 11, 2025 07:50 ET (11:50 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。